Abstract

Sialidosis (MIM 256550) is a rare, autosomal recessive inherited disorder, caused by α-N-acetyl neuraminidase deficiency resulting from a mutation in the neuraminidase gene (NEU1), located on 6p21.33. This genetic alteration leads to abnormal intracellular accumulation as well as urinary excretion of sialyloligosaccharides. A definitive diagnosis is made after the identification of a mutation in the NEU1 gene. So far, 40 mutations of NEU1 have been reported. An association exists between the impact of the individual mutations and the severity of clinical presentation of sialidosis. According to the clinical symptoms, sialidosis has been divided into two subtypes with different ages of onset and severity, including sialidosis type I (normomorphic or mild form) and sialidosis type II (dysmorphic or severe form). Sialidosis II is further subdivided into (i) congenital; (ii) infantile; and (iii) juvenile. Despite being uncommon, sialidosis has enormous clinical relevance due to its debilitating character. A complete understanding of the underlying pathology remains a challenge, which in turn limits the development of effective therapeutic strategies. Furthermore, in the last few years, some atypical cases of sialidosis have been reported as well. We herein attempt to combine and discuss the underlying molecular biology, the clinical features, and the morphological patterns of sialidosis type I and II.

Highlights

  • Sialidosis, an autosomal recessive disorder, occurs due to a structural defect in the neuraminidase gene and is characterized by abnormal tissue accumulation as well as urinary excretion of sialylated oligosaccharides and glycolipids [1].The human neuraminidase gene is located at chromosome band 6p21.3, where the HLA locus is reported to be located [2]

  • The different expression of three enzymes can be explained by the fact that deficiency of each leads to three distinct lysosomal storage disorders (LSDs): galactosialidosis (GS) or protective protein/cathepsin A (PPCA) deficiency with a secondary combined deficiency of Neuraminidase 1 (NEU1) and β-GAL, sialidosis or

  • Table summarizes the clinical features of the sialidosis II, which is characterized by the development of progressive mucopolysaccharidosis-like infantile/juvenile subtype

Read more

Summary

Introduction

Sialidosis, an autosomal recessive disorder, occurs due to a structural defect in the neuraminidase gene and is characterized by abnormal tissue accumulation as well as urinary excretion of sialylated oligosaccharides and glycolipids [1]. Until 1977, deficiency of Neuraminidase 1 (NEU1) was thought to be associated with classical mucolipidosis I, a severe and rapidly progressive lysosomal storage disease with onset at birth or shortly after birth [3,4]. In 1977, the term sialidosis was first used to describe the syndrome of two siblings having a visual impairment and mild neurological manifestations that slowly developed in their adolescence. Enzymatic assays in cultured fibroblasts and leukocytes from these siblings exhibited an isolated deficiency of NEU1 [3,4].

Background
Schematic representation downstreamofofNEU1
Method of Study anddone
Sialidosis I
Sialidosis II
Findings
Therapeutic Interventions for Sialidosis
Conclusions and Future Perspectives
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call